Trial result ·
Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This trial looked at people with hepatitis C who get dialysis for chronic kidney disease. It took place at more than one center. It had 120 people who had not been treated before. Doctors compared sofosbuvir/daclatasvir with grazoprevir/elbasvir. People without cirrhosis were put into a group by chance. People with cirrhosis all got sofosbuvir/daclatasvir. Guidelines rule out the other pair for them.
What they found
All 120 people finished the study. No one dropped out. The main test was whether the virus was gone at week 12. In both groups, every person had no virus found 12 weeks after treatment. Nearly all people had no harmful effects reported.
What it means for patients
The authors say both drug pairs worked very well and were safe. This was for people with hepatitis C who get dialysis. They say sofosbuvir/daclatasvir can be used more widely. They say this covers all stages of liver scarring and all virus types. They add that it costs much less.
Why it is not certain yet
People with cirrhosis were not put into groups by chance. So the drug comparison is less fair for them. The trial was single-blind, so not everyone was kept unaware of the drug given. The abstract does not say how many people got each drug. It gives no results split by virus type. It gives no cost figures to back the cost claim. It also does not report results past week 12.
Source
Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial.
PubMed · PMID 42845083We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Hepatitis C publications